On June 24, Gelunhui reported that Legend Biotech (LEGN.US), which rose 4.44% last Friday (21st), continued to rise 4.55% in pre-market trading today, reaching 44.55 US dollars. Recently, several institutions have issued research reports bullish on the company. Among them, Asthika Goonewardene, an analyst at Bank of America, initiated a buy rating on Legend Biotech with a target price of $88. Edward Tenthoff, an analyst at Piper Sandler, reiterated a shareholding rating and a target price of $90. Leonid Timashev, an analyst at CICC, maintained a buy rating and a target price of $86 for Legend Biotech.
美股异动 | 传奇生物盘前涨超4% 获多家机构看好
Legend Biotech rose more than 4% before the market opens in US stock, receiving bullish opinions from multiple institutions.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.